Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action
Fernando Bril, Kenneth Cusi
Diabetes Care (2017) Vol. 40, Iss. 3, pp. 419-430
Open Access | Times Cited: 312

Showing 51-75 of 312 citing articles:

The protective mechanism ofLactobacillus plantarumFZU3013 against non-alcoholic fatty liver associated with hyperlipidemia in mice fed a high-fat diet
Min Chen, Weiling Guo, Qiuyi Li, et al.
Food & Function (2020) Vol. 11, Iss. 4, pp. 3316-3331
Closed Access | Times Cited: 67
The triglyceride-glucose index is associated with the severity of hepatic steatosis and the presence of liver fibrosis in non-alcoholic fatty liver disease: a cross-sectional study in Chinese adults
Wen Guo, Jing Lü, Pei Qin, et al.
Lipids in Health and Disease (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 66
Activating Adenosine Monophosphate–Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice
Qian Lin, Zhifeng Huang, Genxiang Cai, et al.
Hepatology (2020) Vol. 73, Iss. 6, pp. 2206-2222
Open Access | Times Cited: 64
Effect of Blueberry Consumption on Cardiometabolic Health Parameters in Men with Type 2 Diabetes: An 8-Week, Double-Blind, Randomized, Placebo-Controlled Trial
Kim S. Stote, Margaret Wilson, Deborah Hallenbeck, et al.
Current Developments in Nutrition (2020) Vol. 4, Iss. 4, pp. nzaa030-nzaa030
Open Access | Times Cited: 62
Beyond Body Weight-Loss: Dietary Strategies Targeting Intrahepatic Fat in NAFLD
Nicolai Worm
Nutrients (2020) Vol. 12, Iss. 5, pp. 1316-1316
Open Access | Times Cited: 60
Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease
Hamza El Hadi, Angelo Di Vincenzo, Roberto Vettor, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 9, pp. 2215-2215
Open Access | Times Cited: 58
Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
Byung‐Wan Lee, Yong‐ho Lee, Cheol‐Young Park, et al.
Diabetes & Metabolism Journal (2020) Vol. 44, Iss. 3, pp. 382-382
Open Access | Times Cited: 58
Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
Kenneth Cusi
Diabetes Care (2020) Vol. 43, Iss. 2, pp. 275-279
Open Access | Times Cited: 56
Established and emerging factors affecting the progression of nonalcoholic fatty liver disease
Stergios Kechagias, Patrik Nasr, Julia Blomdahl, et al.
Metabolism (2020) Vol. 111, pp. 154183-154183
Open Access | Times Cited: 56
Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting
Joana Vieira Barbosa, Michelle Lai
Hepatology Communications (2020) Vol. 5, Iss. 2, pp. 158-167
Open Access | Times Cited: 56
Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis
Asad Izziddin Dajani, Branko Popović
World Journal of Clinical Cases (2020) Vol. 8, Iss. 21, pp. 5235-5249
Open Access | Times Cited: 54
The synergistic effect of Citrus bergamia and Cynara cardunculus extracts on vascular inflammation and oxidative stress in non-alcoholic fatty liver disease
Vincenzo Musolino, Micaela Gliozzi, Ezio Bombardelli, et al.
Journal of Traditional and Complementary Medicine (2020) Vol. 10, Iss. 3, pp. 268-274
Open Access | Times Cited: 53
Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?
Jeffrey Budd, Kenneth Cusi
The American Journal of Medicine (2020) Vol. 133, Iss. 5, pp. 536-543
Closed Access | Times Cited: 52
Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review
Xiaodan Lv, Yongqiang Dong, Lingling Hu, et al.
Endocrinology Diabetes & Metabolism (2020) Vol. 3, Iss. 3
Open Access | Times Cited: 51
Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
Jeffrey Budd, Kenneth Cusi
Current Diabetes Reports (2020) Vol. 20, Iss. 11
Closed Access | Times Cited: 51
Novel Sesquiterpene Glycoside from Loquat Leaf Alleviates Type 2 Diabetes Mellitus Combined with Nonalcoholic Fatty Liver Disease by Improving Insulin Resistance, Oxidative Stress, Inflammation, and Gut Microbiota Composition
Chen Jian, Xiaoqin Ding, Ruoyun Wu, et al.
Journal of Agricultural and Food Chemistry (2021) Vol. 69, Iss. 47, pp. 14176-14191
Closed Access | Times Cited: 46
DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases
Yehuda Handelsman, John E. Anderson, George L. Bakris, et al.
Journal of Diabetes and its Complications (2021) Vol. 36, Iss. 2, pp. 108101-108101
Open Access | Times Cited: 44
Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers
Rita Basu, Mazen Noureddin, Jeanne M. Clark
Mayo Clinic Proceedings (2022) Vol. 97, Iss. 9, pp. 1700-1716
Open Access | Times Cited: 34
The metabolic triad of non‐alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment
Bertrand Cariou
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. S2, pp. 15-27
Closed Access | Times Cited: 31
Hepatic, Extra-hepatic Outcomes and Causes of Mortality in NAFLD – An Umbrella Overview of Systematic Review of Meta-Analysis
Jieling Xiao, Cheng Han Ng, Kai En Chan, et al.
Journal of Clinical and Experimental Hepatology (2022) Vol. 13, Iss. 4, pp. 656-665
Open Access | Times Cited: 31
Canagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy
Zhipeng Xu, Wenxin Hu, Bin Wang, et al.
Yonsei Medical Journal (2022) Vol. 63, Iss. 7, pp. 619-619
Open Access | Times Cited: 28
Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Da Hea Seo, Young Ju Suh, Yongin Cho, et al.
Diabetes & Metabolism Journal (2022) Vol. 46, Iss. 4, pp. 630-639
Open Access | Times Cited: 27
Therapeutic efficacy of liraglutide versus metformin in modulating the gut microbiota for treating type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease
Ying Xing, Zheng Rongjiong, Mayila Kahaer, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 20
Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus
Noboru Kurinami, Seigo Sugiyama, Akira Yoshida, et al.
Diabetes Research and Clinical Practice (2018) Vol. 142, pp. 254-263
Closed Access | Times Cited: 55
Glucagon like Peptide-1 Receptor Agonists for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: A Novel Therapeutic Option
Gauri Dhir, Kenneth Cusi
Journal of Investigative Medicine (2017) Vol. 66, Iss. 1, pp. 7-10
Closed Access | Times Cited: 51

Scroll to top